Top ▲

Arrhythmogenic cardiomyopathy

Disease ID:1268
Name:Arrhythmogenic cardiomyopathy
Associated with:0 target
1 immuno-relevant ligand
Activation of inflammatory signalling is a prominent feature of arrhythmogenic cardiomyopathy (ACM), and appears to drive key features of the disease.


No target related data available for Arrhythmogenic cardiomyopathy


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
BAY 11-7082 1
Immuno Disease Comments: Inhibition of NF-κB by BAY 11-7082 has been used to determine that reducing the elevated inflammatory signalling that is present in ACM modulates key features of the disease.
Bioactivity Comments: Suggested molecular targets include IκBα and the ubiquitin conjugating enzymes Ubc13 (aka UBE2N) and UbcH7 (aka UBE2L3) [2]. | View biological activity


Show »

1. Chelko SP, Asimaki A, Lowenthal J, Bueno-Beti C, Bedja D, Scalco A, Amat-Alarcon N, Andersen P, Judge DP, Tung L et al.. (2019) Therapeutic Modulation of the Immune Response in Arrhythmogenic Cardiomyopathy. Circulation, 140 (18): 1491-1505. [PMID:31533459]

2. Strickson S, Campbell DG, Emmerich CH, Knebel A, Plater L, Ritorto MS, Shpiro N, Cohen P. (2013) The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J, 451 (3): 427-37. [PMID:23441730]